Advising XOMA Royalty on its Acquisition of Mural Oncology

We were pleased to advise XRA 5 Corp on its acquisition of Mural Oncology plc. XRA is a wholly owned subsidiary of XOMA Royalty.

The acquisition is being effected by a recommended offer by way of scheme of arrangement under the Irish Takeover Rules.

The acquisition represents a significant milestone for XOMA Royalty Corporation, strengthening its portfolio of royalty interests and expanding its exposure to cutting-edge oncology assets. This transaction highlights XOMA’s commitment to supporting the advancement of transformative therapies in the life sciences space.

Mural Oncology, headquartered in Dublin, is a clinical-stage biotechnology company focused on the development of novel immuno-oncology therapies. Its pipeline includes a range of innovative treatments targeting hard-to-treat cancers, supported by a strong research and development platform and strategic collaborations within the sector.

Our team was led by Justin McKenna with support from Paul Egan, Anne Harkin, Caitríona Nic Bhloscaidh, Dean Molyneux, Alex Dunne and Rachel Kilkenny from our Corporate team. Nick Metcalfe and Eavan Walsh from our Corporate Governance team. Marie Jennings, Niamh Caffrey, Susan Lynch and Carl Grenville from our Tax team and Tara Kelly and Hannah McCarthy from our Competition and Antitrust team.

Read the full press release here.

For more information and expert legal advice, please get in touch.